Reducing Stasis Outcomes for Depression in Group Behavioural Activation Therapy
Effect of Treatment Augmentations Embedded in Behavioural Activation Group Therapy on Reducing Drop-out and Stasis Rates in Depression
1 other identifier
interventional
34
1 country
1
Brief Summary
Depression is one of the most common mental health disorders and it is estimated up to 50% of patients do not respond to evidenced-based psychotherapy treatment, recording a 'stasis' outcome. However, there is limited research understanding this population, meaning a considerable number of people continue to suffer. The purpose of this study is to 1) identify depression stasis prevalence and predictors in an existing evidenced-based group treatment for depression, 2) run a clinical trial to test whether an embedded intervention based on theoretical and clinical practice evidence can help reduce patient depression stasis and drop-out rates and 3) understand what aspect of therapy produces change (or prevents change in stasis). The study will be based on behavioural activation (BA) therapy delivered in an eight-session group format in an Improving Access to Psychological Therapies (IAPT) service in the United Kingdom. BA is one of the most effective psychotherapies available for depression and focuses on helping patients to increase their engagement with valued activities to help break out of the cycle of depression. Firstly, an archived anonymised dataset of routine depression measures from patients who have previously received the existing group BA treatment will be analysed. Secondly, the group BA treatment delivered to patients in 2017 will be enhanced with two treatment augmentations. One augmentation will target stasis outcomes through the addition of specific 'if-then' planning (known as implementation intentions) when setting between-session homework and the other augmentation will target patient drop-out by informing patients about group BA effectiveness and therapy-dose evidence. The stasis outcomes and drop-out rates from the enhanced treatment in the trial will be compared with the archived outcomes to see if the intervention has had an effect and the role of engaging in valued living as a mechanism of change for depression symptoms will be examined. It is hypothesised that a) 50% of patients who have received the existing BA group treatment for depression will have a stasis outcome, b) there will be a significant reduction in depression stasis outcomes and drop-out rate following the enhanced BA group treatment delivered in the trial and c) engagement in valued living will have a mediating effect on outcome for responding patients following the enhanced BA group treatment but the effect will not be present for patients with a stasis outcome.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable depression
Started Dec 2016
Shorter than P25 for not_applicable depression
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 11, 2016
CompletedFirst Posted
Study publicly available on registry
November 21, 2016
CompletedStudy Start
First participant enrolled
December 1, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2017
CompletedMay 4, 2018
May 1, 2018
1 year
November 11, 2016
May 1, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in Patient Health Questionnaire (PHQ-9) scores
Validated 9-item self-report measure of depressive symptoms
Week 1 (pre-treatment), at every weekly treatment session attended (for 8 weeks) and at week 8 (end of treatment)
Secondary Outcomes (4)
Patient attendance at treatment sessions
Weeks 1-8 (every weekly treatment session - maximum of 8)
Change in Valued Living Questionnaire (VLQ) score
Week 1 (pre-treatment), week 4 (at the 4th treatment session) and at week 8 (end of treatment)
Change in Generalised Anxiety Disorder Assessment (GAD-7) score
Week 1 (pre-treatment), at every weekly treatment session attended (for 8 weeks) and at week 8 (end of treatment)
Change in Work and Social Adjustment Scale (WSAS) score
Week 1 (pre-treatment), at every weekly treatment session attended (for 8 weeks) and at week 8 (end of treatment)
Other Outcomes (1)
Behavioural activation group (BAG) therapy adherence
Weeks 1-8 (Every treatment session)
Study Arms (1)
Enhanced Behavioural Activation Groups
EXPERIMENTALBehavioural activation group (BAG) psychotherapy delivered with two embedded treatment augmentations; 1. Implementation intentions 2. Dose-response psychoeducation
Interventions
Behavioural activation (BA) is a psychotherapy intervention based on behaviour theory and operant conditioning. It teaches patients to reduce avoidant depressive behaviours and in turn increase the positive reinforcement they receive from their environment for non-depressive behaviours through the use of activity scheduling and pleasant events. For the trial, BA will be delivered in a group format (BAG) and facilitated by two therapists. BAG treatment will consist of eight weekly sessions, lasting two hours and will follow a manualised treatment protocol. Each session will be based on a different topic relevant to the principles of BA and patients will be given between session work to complete to encourage increased participation in rewarding personally meaningful activities.
Eligibility Criteria
You may qualify if:
- Patients who access the Sheffield Improving Access to Psychological Therapies (IAPT) service (United Kingdom) with depression as the primary presenting problem
- Patients with co-morbid anxiety symptoms can be included as long as depression is the primary diagnosis
- Are referred to and choose the Behavioural Activation Group (BAG) treatment option
- Able to attend the BAG intervention
- Aged 18 or over
You may not qualify if:
- Primary diagnosis that is not depression
- Patients who do not choose BAG as a treatment option
- Aged under 18
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Sheffieldlead
- Sheffield Health and Social Care NHS Foundation Trustcollaborator
- Howard Morton Trustcollaborator
Study Sites (1)
Sheffield Health and Social Care NHS Foundation Trust - Improving Access to Psychological Therapies Service
Sheffield, South Yorkshire, S3 7ND, United Kingdom
Related Publications (1)
Gollwitzer, P. M. (1999). Implementation intentions: Strong effects of simple plans. American Psychologist, 54, 493-503.
BACKGROUND
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Melanie K Simmonds-Buckley, BSc
University of Sheffield
- PRINCIPAL INVESTIGATOR
Stephen Kellett, DClinPsy
University of Sheffield & Sheffield Health and Social Care NHS Foundation Trust
- PRINCIPAL INVESTIGATOR
Glenn Waller, PhD
University of Sheffield
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- PhD Research Student
Study Record Dates
First Submitted
November 11, 2016
First Posted
November 21, 2016
Study Start
December 1, 2016
Primary Completion
December 1, 2017
Study Completion
December 1, 2017
Last Updated
May 4, 2018
Record last verified: 2018-05
Data Sharing
- IPD Sharing
- Will not share
The data will be anonymised and analysed collectively so individual participant data will not be identifiable within any reports or publications.